"In addition, multiple secondary endpoints will be
Post# of 72447
(Total Views: 200)
Posted On: 11/30/2017 9:32:29 AM
"In addition, multiple secondary endpoints will be studied to provide further insights into the potential benefits of Prurisol compared to marketed therapies, both oral and biologic."
Clearly they are NOT going to make the mistake that several other companies have made. Those other companies rushed to get their results out, and did not do their statistical analyses in a way that made it clear to non-experts what the actual efficacy with each patient category was.
IPIX is going to take its time to analyze the data so that statistics are sliced and diced in every way possible, to show what the efficacy really is and in comparison with other drugs.
They wouldn't be doing that if it didn't work, would they?
Clearly they are NOT going to make the mistake that several other companies have made. Those other companies rushed to get their results out, and did not do their statistical analyses in a way that made it clear to non-experts what the actual efficacy with each patient category was.
IPIX is going to take its time to analyze the data so that statistics are sliced and diced in every way possible, to show what the efficacy really is and in comparison with other drugs.
They wouldn't be doing that if it didn't work, would they?
(5)
(0)